In situ pharmacoproteomics for the prediction of efficacy and side effects

Research Project

Project/Area Number	26640098
Research Category	Grant-in-Aid for Challenging Exploratory Research
Allocation Type	Multi-year Fund
Research Field	Tumor diagnostics
Research Institution	National Institutes of Biomedical Innovation, Health and Nutrition
Principal Investigator	ADACHI JUN 国立研究開発法人医薬基盤・健康・栄養研究所, プロテオームリサーチプロジェクト, 研究員 (20437255)
Project Period (FY)	2014-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000) Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000) Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords	キナーゼ阻害剤 / プロテオミクス
Outline of Final Research Achievements	We developed a 3D-Pharmacoproteomics (3D-PPx）method to identify targets of ATP-competitive kinase inhibitors at the various scale of concentrations and inhibition time points. We applied 3D-PPx to find targets of erlotinib, an EGFR inhibitor used as an anti-cancer drug. We confirmed that 3D-PPx can detect the effect of EGFR mutation using erlotinib-resistant NSCLC cells which express wild-type EGFR and erlotinib-sensitive NSCLC cells which express mutant EGFR. Furthermore, several target candidates of erlotinib were identified using 3D-PPx.

Report

(3 results)